Wegovy injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU NovoNordisk The European Medicines Agency (EMA) has approved an update to the product information for Wegovy injection that allows the medicine to stay at a controlled temperature of up to 30C for up to 48 hours during delivery, reducing distribution complexity for pharmacies and online partners
Hydration, gradual fiber intake, movement, and consistency are key strategies for regular bowel movements while taking GLP-1 medications
Drug Interactions The concomitant use of JANUMET with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)]
In this population, 53% of individuals had commercial health insurance, 18% had Medicare, 11% had Medicaid, 1% had Dual (Medicare/Medicaid) coverage, and 17% had other coverage (e.g., Tricare, Veterans Affairs, or other State or local programs)
